1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders
US-2015353510-A1 · Dec 10, 2015 · US
US9296708B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9296708-B2 |
| Application number | US-201414480204-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 8, 2014 |
| Priority date | May 13, 2008 |
| Publication date | Mar 29, 2016 |
| Grant date | Mar 29, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (ABT) moiety covalently bonded to a cell binding terminus (CBT) through a linker and optionally, a connector molecule.
Opening claim text (preview).
The invention claimed is: 1. A compound according to the chemical structure: wherein A is an antibody binding moiety according to the chemical formula: Where Y′ is H or NO 2 ; X is O, CH 2 , NR 1 , S(O), S(O) 2 , —S(O) 2 O, —OS(O) 2 , or OS(O) 2 O; R 1 is H, a C 1 -C 3 alkyl group, or a —C(O)(C 1 -C 3 ) group; X′ is CH 2 , O, N—R 1 ′ or S; R 1′ is H or C 1 -C 3 alkyl; Z is a bond, a monosaccharide, disaccharide, oligosaccharide, glycoprotein or glycolipid; X b is a bond, O, CH 2 , NR 1 or S; X″ is O, CH 2 , NR 1 ; R 1 is H, a C 1 -C 3 alkyl group or a —C(O)(C 1 -C 3 ) group; n is 1 or 2; n 1 is 1; B is a cell binding moiety according to the chemical formula: Where X 1 and X 2 are each independently CH 2 , O, NH or S; X 3 is O, CH 2 , NR 1 , S(O), S(O) 2 , —S(O) 2 O, —OS(O) 2 , or OS(O) 2 O; R 1 is H, a C 1 -C 3 alkyl group, or a —C(O)(C 1 -C 3 ) group; k is an integer from 1 to 15; L is a linker according to the chemical formula: Or L is a polyethylene gycol, polypropylene glycol or polypropylene-co-polyethylene glycol linker having between 1 and 20 glycol units; Where R a is H, C 1 -C 3 alkyl or alkanol or forms a proline side chain with R 3 R 3 forms a proline side chain with R a or is a side chain derived from an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartic acied, cysteine, glutamine, glutamic acid, glycine, histicine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan and valine; and m is an integer from 1 to 30; or L is a linker according to the chemical formula: Where Z and Z′ are each independently a bond, —(CH 2 ) i —O, —(CH 2 ) i —S, —(CH 2 ) i —N—R , wherein said —(CH 2 ) i group, if present in Z or Z′, is bonded to[CON] if present, antibody binding terminus (ABT) or cell binding terminus (CBT); Each R is independently H, or a C 1 -C 3 alkyl or alkanol group; Each R 2 is independently H or a C 1 -C 3 alkyl group; Each Y is independently a bond, O, S or N—R; Each i is independently 0 to 100; D is or a bond, with the proviso that Z, Z′ and D are not each simultaneously bonds; j is 1 to 100; m′ is 1 to 100; n′ is 1 to 100; and X 1 is O, S or N—R, R is as defined above; and [CON] is a bond or a moiety according to the chemical structure: Where X 2 is O, S, NR 4 , S(O), S(O) 2 , —S(O) 2 O, —OS(O) 2 , or OS(O) 2 O; X 3 is NR 4 , O or S; and R 4 is H, a C 1 -C 3 alkyl or alkanol group, or a —C(O)(C 1 -C 3 ) group; or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1 wherein A is X is O or NH; Y′ is H; X′ is O; and Z is a bond, a monosaccharide or a disaccharide; and Where X b is a bond or O, or a pharmaceutically acceptable salt thereof. 3. The compound according to claim 1 wherein A is 4. The compound according to claim 1 wherein A is 5. The compound according to claim 4 wherein X′ is O or N—R 1 ′ and R 1 ′ is H. 6. The compound according to claim 4 wherein X′ is O. 7. The compound according to claim 2 wherein A is 8. The compound according to claim 4 wherein Z is a monosaccharide selected from the group consisting of aldoses, ketoses and aminosugars. 9. The compound according to claim 4 wherein Z is a monosaccharide selected from the group consisting of D-glyceraldehdye, D-erythrose, D-Threose, D-ribose, D-arabinose, D-xylose, D-lyxose, D-allose, D-altrose, D-Glucose, D-Mannose, D-gulose, D-idose, D-galactose, dihydroxyacetone, D-erythrulose, D-ribulose, D-xylulose, D-Psicose, D-Fructose, D-Sorbose, D-Tagatose, galactoseamine, sialic acid and N-acetylglucosamine. 10. The compound according to claim 4 wherein Z is a disaccharide selected from the group consisting of sucrose, which may be optionally N-acetylated, lactose, which may be optionally N-acetylated, maltose, which may be optionally N-acetylated, trehalose, which may be optionally N-acetylated, cellobiose, which may be optionally N-acetylated, kojibiose, which may be optionally N-acetylated, nigerose, which may be optionally N-acetylated, isomaltose, which may be optionally N-acetylated, β,β-trehalose, which may be optionally N-acetylated, sophorose, which may be optionally N-acetylated, laminaribiose, which may be optionally N-acetylated, gentiobiose, which may be optionally N-acetylated, turanose, which may be optionally N-acetylated, maltulose, which may be optionally N-acetylated, palatinose, which may be optionally N-acetylated, mannobiose, which may be optionally N-acetylated, melibiose, which may be optionally N-acetylated, melibiulose, which may be optionally N-acetylated, rutinose, which may be optionally N-acetylated, rutinulose, which may be optionally N-acetylated and xylobiose, which may be optionally N-acetylated. 11. The compound according to claim 1 wherein said linker is group according to the chemical formula: Where R a is H or forms a proline side chain with R 3 and R 3 forms a proline side chain with R a or is a side chain derived from an amino acid selected from the group consisting of alanine, arginine, asparagine, aspartic acied, cysteine, glutamine, glutamic acid, glycine, histicine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan and valine; and m is an integer from 1 to 10. 12. The compound according to claim 1 wherein [CON] is a group, where X 2 is O, S or NR 4 ; and R 4 is H or a C 1 -C 3 alkyl or alkanol group. 13. The compound according to claim 1 wherein said linker is a group according to the formula: Wherein m is an integer from 1 to 10.
Human Necessities · mapped topic
1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles · CPC title
1,2,3-Triazoles · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids} · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.